Table 3.
Univariable and multivariable logistic regression model to identify covariates associated with late CTCAE genitourinary toxicity after CRT.
| Covariates | Level | CTCAE Grade 2+ GU Late Toxicity (6–24 Months) | CTCAE Grade 2+ GU Persistent Late Toxicity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No (n = 345) |
Yes (n = 84) |
Univariable | Multivariable (n = 411) |
No (n = 406) |
Yes (n-27) |
Univariable | Multivariable (n = 427) |
||||||
| N (%) or Median (IQR) |
N (%) or Median (IQR) |
OR (95% CI) |
p value |
OR (95% CI) |
p value |
N (%) or Median (IQR) |
N (%) or Median (IQR) |
OR (95% CI) |
p value |
OR (95% CI) |
p value |
||
| Baseline grade 2+ GU toxicity |
No Yes missing |
335 (98) 7 (2) 3 |
72 (86) 12 (14) 0 |
7.98 (3.03-20.96) | <0.0001 | 6.73 (2.19-20.7) | 0.001 | 392 (97) 11 (3) 3 |
19 (70) 8 (30) 0 |
15.0 (5.41-41.63) |
<0.0001 | 7.78 (2.43-24.85) | 0.001 |
| Baseline IPSS score |
Median (n) |
6 (2-11) (n=299) |
8 (5-13) (n=75) |
1.05 (1.01-1.09) | 0.009 |
6 (3-11) (n=351) |
10 (6-12) (n=27) |
1.04 (0.99-1.10) | 0.093 | ||||
| Baseline EPIC-26 overall urinary bother score |
Median (n) |
100 (75-100) (n=321) |
75 (50-100) (n=78) |
0.98 (0.97-0.99) | <0.0001 | 100 (75-100) (n=377) |
75 (50-100) (n=26) |
0.99 (0.97-0.99) | 0.03 | ||||
| Worst acute grade 2+ GU Toxicity |
No Yes missing |
277 (80) 68 (20) 0 |
49 (59) 34 (41) 1 |
2.83 (1.69-4.71) | <0.0001 |
2.26 (1.30-3.95) | 0.004 | 319 (79) 85 (21) 2 |
9 (35) 17 (65) 1 |
7.09 (3.05-16.46) |
<0.0001 | 4.84 (1.98-11.83) | 0.001 |
| Persistent grade 2+ acute GU toxicity |
No Yes |
328 (95) 17 (5) |
60 (71) 24 (29) |
7.72 (3.91-15.22) |
<0.0001 | 381 (94) 25 (6) |
11 (41) 16 (59) |
22.17 (9.31-52.79) |
<0.0001 | ||||
| Worst acute IPSS score |
Median (n) |
11.5 (7-18) (n=336) |
17 (12-21) (n=83) |
1.08 (1.05-1.12) | <0.0001 | 12 (7-18) (n=394) |
17 (14-22) (n=27) |
1.09 (1.03-1.15) | 0.001 | ||||
| Worst acute EPIC-26 overall urinarybother |
Median (n) |
75 (50-100) (n=333) |
50 (25-75) (n=81) |
0.97 (0.97-0.98) | <0.0001 | 75 (50-100) (n=389) |
50 (25-75) (n=27) |
0.97 (0.96-0.99) | <0.0001 | ||||
| Worst acute urinary symptoms Grade 2+ obstructive Grade 2+ irritative Grade 2+ pain/dysuria Grade 2+ incontinence Grade 1+ haematuria |
No Yes No Yes No Yes No Yes No Yes |
328 (95) 17 (5) 297 (86) 48 (14) 332 (96) 13 (4) 341 (99) 4 (1) 335 (97) 10 (3) |
69 (83) 14 (17) 60 (72) 23 (28) 78 (94) 5 (6) 78 (94) 5 (6) 77 (93) 6 (7) |
3.91 (1.84-8.32) 2.37 (1.34-4.19) 1.64 (0.57-4.73) 5.46 (1.34-20.82) 2.62 (0.92-7.40) |
<0.0001 0.003 0.36 0.01 0.07 |
384 (95) 20 (5) 341 (84) 63 (16) 388 (96) 16 (4) 398 (99) 6 (1) 389 (96) 15 (4) |
15 (58) 11 (42) 18 (69) 8 (31) 24 (92) 2 (8) 23 (88) 3 (12) 25 (96) 1 (4) |
14.1 (5.73-34.58) 2.31 (1.00-5.77) 2.02 (0.44-9.30) 8.65 (2.03-36.82) 1.04 (0.13-8.17) |
<0.0001 0.05 0.37 0.003 0.97 |
||||
| Age | Median (n) |
69 (65-74) (n=345) |
68.5 (65-73) (n=84) |
1.00 (0.96-1.04) | 0.95 | 0.97 (0.93-1.02) | 0.22 | 69 (65-73) (n=406) |
69 (66-75) (n=27) |
1.03 (0.97-1.10) | 0.38 | ||
| Prostate Volume (cm3) |
Median (n) |
43 (32-55) (n=333) |
47 (37-68) (n=81) |
1.02 (1.01-1.03) | 0.002 | 1.02 (1.00-1.03) | 0.009 | 43 (33-57) (n=389) |
44 (33-60) (n=27) |
1.00 (0.98-1.02) | 0.82 | ||
| Risk group (intermediate) |
low Int |
37 (11) 308 (89) |
6 (7) 78 (93) |
1.56 (0.63-3.83) | 0.33 | 1.73 (0.63-4.76) | 0.29 | 42 (10) 364 (90) |
1 (4) 26 (96) |
3 (0.40-22.66) | 0.29 | ||
| Baseline urinary medication (Yes) |
No Yes |
275 (80) 70 (20) |
61 (73) 23 (27) |
1.48 (0.86-2.56) | 0.16 | 1.20 (0.64-.2.23) | 0.57 | 322 (79) 84 (21) |
17 (63) 10 (37) |
2.25 (1.00-5.10) | 0.05 | ||
| Fiducial use (Yes) | No Yes |
144 (42) 201 (58) |
41 (49) 43 (51) |
0.75 (0.47-1.21) | 0.24 | 168 (41) 238 (59) |
19 (70) 8 (30) |
0.30 (0.13-0.69) | 0.005 | 0.43 (0.17-1.06) | 0.07 | ||
OR = odds ratio; IQR = interquartile range; GU = genitourinary; IPSS = international Prostate Symptom Score; EPIC = Expanded Prostate Cancer Index Composite; Int = intermediate.